Commonly Prescribed Anticoagulants Exert Anticancer Effects in Oral Squamous Cell Carcinoma Cells In Vitro

Biology

Camile S. Farah¹  Michael McCullough²  Antonio Celentano²  Zichen Lin²  Li-Qiao R. Ling²  Rita Paolini²  Mathew A. W. T. Lim² 

[1]Australian Centre for Oral Oncology Research & Education, Perth, WA 6009, Australia

[2]Melbourne Dental School, The University of Melbourne, 720 Swanston Street, Carlton, VIC 3053, Australia

关键词: oral cancer;    oral squamous cell carcinoma;    anticoagulants;    heparin;    warfarin;    edoxaban;   

DOI  :  10.3390/biology11040596

来源: DOAJ

【 摘 要 】

Oral squamous cell carcinoma (OSCC) is the most common head and neck cancer. With anticoagulant usage on the rise, it is important to elucidate their potential effects on tumour biology and interactions with chemotherapeutics. The aim of the present study was to investigate the effects of anticoagulants on OSCC cell lines and their interactions with the drug 5-fluorouracil (5-FU). Cell proliferation was assessed using an MTS in vitro assay in two human OSCC cell lines (H357/H400) and in normal oral keratinocytes (OKF6) treated with the 5-FU (0.2/1/5/10 μg/mL), conventional anticoagulants warfarin (1/5/10/20 μM) and heparin (5/20/80 U), as well as four new oral anticoagulants, dabigatran (5/10/20 μM), rivaroxaban (5/10/20 μM), apixaban (0.1/1/5 μg/mL), and edoxaban (5/10/20 μM). Cell migration was assessed at 3 h intervals up to18 h using a wound healing assay. Our results clearly demonstrate, for the first time, that commonly prescribed anticoagulants exert in vitro antiproliferative effects on OSCC cells. Furthermore, treatment with some anticoagulants reduced the migration of OSCC cell lines. Nevertheless, most of the anticoagulants tested reduced the effectiveness of the chemotherapeutic agent tested, 5-FU, highlighting potential flaws in the current pharmacological management of these patients. Our findings showed the need for the immediate translation of this research to preclinical animal models.

【 授权许可】

Unknown